These guides are AI-generated educational summaries — not legal or medical advice.
C&P Exam Prep: Autoimmune Diseases (Lupus / Rheumatoid Arthritis / Gout)
DBQ Overview
Interview + Physical- Form Name
- Systemic_Lupus_Erythematosus_and_Other_Autoimmune_Diseases
- Form Code
- Systemic_Lupus_Erythematosus_and_Other_Autoimmune_Diseases
- Page Count
- 9
- Examiner Type
- Rheumatologist or Physician
- Estimated Duration
- 30-45 minutes
- Exam Format
- Interview + Physical
What to Expect During Your Exam
Exam Overview
To document the diagnosis, severity, organ system involvement, treatment regimen, and functional impact of your autoimmune condition (SLE, RA, gout, or related autoimmune disease) for VA disability rating purposes under 38 CFR 4.88b and 4.71a.
What the examiner evaluates:
- Confirmed diagnosis and diagnostic code (e.g., SLE, RA, gout, scleroderma, Sj-gren's syndrome, polymyalgia rheumatica, Wegener's granulomatosis, Goodpasture's syndrome, Guillain-Barr- syndrome)
- Disease activity level and frequency of flare-ups or exacerbations
- Organ system involvement: skin, joints, kidneys, lungs, heart, blood, neurological, vascular
- Current medications and treatment intensity (oral corticosteroids, immunosuppressives, biologics, topical agents)
- Laboratory and serological findings (ANA, anti-dsDNA, anti-Smith, anti-Ro, complement C3/C4, CBC, CRP, ESR, urinalysis, BMP)
- Hematologic manifestations (anemia, leukopenia, thrombocytopenia)
- Renal involvement (glomerulonephritis, proteinuria, creatinine/BUN/eGFR abnormalities)
- Cardiovascular involvement (pericarditis, myocarditis, Libman-Sacks endocarditis, valvular disease, coronary artery vasculitis)
- Pulmonary involvement (pleuritis, pulmonary emboli, pulmonary hypertension, shrinking lung syndrome)
- Cutaneous manifestations (malar rash, discoid rash, photosensitivity, alopecia, oral ulcers)
- Joint involvement and affected joints
- Neuropsychiatric manifestations
- Impact on daily functioning, work, and quality of life
- Whether incapacitating episodes have occurred and their frequency and duration
- Imaging studies (X-ray, MRI, CT)
- Coexisting autoimmune conditions
Exam may be conducted in person at a VA medical center, VAMC-affiliated clinic, or contracted facility (e.g., LHI/QTC). Telehealth/virtual exams are possible for records review. Request an in-person exam if your condition has significant physical manifestations. You have the right to record the exam in most states - notify the examiner at the start.
Typical duration: 30-45 minutes
Antinuclear Antibody (ANA) Titer
Presence and titer of antinuclear antibodies; a hallmark serological marker for SLE and other autoimmune diseases.
What to expect:
Blood test result from prior lab work reviewed by examiner. A titer of -1:80 is considered positive for SLE diagnostic criteria. The examiner will ask for dates and results.
Key thresholds:
- -1:80 — Supports SLE diagnosis; positive ANA is one of the ACR/EULAR classification criteria for SLE.
- High titer (-1:320) — Strongly associated with active SLE; supports higher severity rating.
Tips:
- Bring printed copies of all ANA results with dates.
- Note that a positive ANA alone does not confirm SLE - the examiner will look at the full clinical picture.
- If anti-dsDNA antibodies are positive, note those results separately as they are highly specific for SLE.
Pain considerations: N/A - laboratory test, not a physical measurement.
Anti-dsDNA and Anti-Smith Antibodies
Highly specific antibodies for SLE diagnosis and disease activity monitoring.
What to expect:
Blood test results reviewed from records. Rising anti-dsDNA titers often correlate with SLE flares. The DBQ specifically asks for anti-Ro antibody, anti-Smith antibody, and anti-phospholipid antibody results.
Key thresholds:
- Positive anti-dsDNA — Highly specific for SLE; supports diagnosis and may correlate with renal involvement.
- Positive anti-Smith — Highly specific for SLE; supports diagnosis.
- Positive anti-phospholipid — Associated with antiphospholipid syndrome, recurrent thrombosis, which can affect disability rating.
Tips:
- Know your antibody profile before the exam.
- If you have positive anti-phospholipid antibodies with a history of clotting events, communicate this clearly.
- Bring the most recent laboratory results for all antibody tests.
Pain considerations: N/A - laboratory test.
Complete Blood Count (CBC) with Differential
Hematologic manifestations of autoimmune disease including hemoglobin, hematocrit, RBC count, WBC count with differential (lymphopenia), and platelet count.
What to expect:
Examiner reviews prior lab results. Key abnormalities include hemolytic anemia (hemoglobin <10), leukopenia/lymphopenia (<1,500 cells/-L), and thrombocytopenia (<100,000/-L).
Key thresholds:
- Hemoglobin <10 g/dL — Hemolytic anemia is an SLE classification criterion and may support higher severity rating.
- WBC <4,000 or lymphocytes <1,500/-L — Leukopenia/lymphopenia is an SLE classification criterion.
- Platelets <100,000/-L — Thrombocytopenia is an SLE classification criterion; severe thrombocytopenia may be life-threatening.
Tips:
- Bring your most recent CBC and any historical CBCs showing abnormalities.
- Tell the examiner if you have ever been hospitalized or treated for severe anemia, bleeding, or clotting due to your autoimmune disease.
- Note if your WBC has been persistently low, increasing your infection risk.
Pain considerations: N/A - laboratory test, but mention fatigue, weakness, shortness of breath associated with anemia.
Renal Function Panel (BUN, Creatinine, eGFR)
Kidney function and the presence of lupus nephritis or other autoimmune-related renal disease.
What to expect:
Examiner reviews prior lab results. Abnormal creatinine, BUN, and reduced eGFR indicate renal impairment. Proteinuria and urinalysis findings (protein, blood, hyaline/granular casts, glucose) are also assessed.
Key thresholds:
- Creatinine >1.5 mg/dL — Indicates renal impairment potentially due to lupus nephritis.
- eGFR <60 mL/min — Moderate-severe chronic kidney disease; may independently affect disability rating.
- Proteinuria >0.5g/24h — Renal criterion for SLE; supports lupus nephritis diagnosis.
Tips:
- Bring all urinalysis results, especially if you have ever had proteinuria or hematuria.
- If you have been diagnosed with lupus nephritis, glomerulonephritis, or membranoproliferative glomerulonephritis, state this clearly.
- Report any symptoms of kidney involvement: swelling (edema), foamy urine, high blood pressure, decreased urine output.
Pain considerations: Mention swelling, hypertension, and any dialysis history.
Inflammatory Markers (ESR and CRP)
Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) measure systemic inflammation and disease activity.
What to expect:
Examiner reviews prior lab results. Elevated ESR and CRP correlate with active disease and flares.
Key thresholds:
- ESR >50 mm/hr — Elevated indicates active inflammation; supports active disease claim.
- CRP >10 mg/L — Elevated CRP indicates active systemic inflammation.
Tips:
- Bring records showing ESR/CRP values during disease flares, not just when you are stable.
- Note if inflammatory markers have been persistently elevated despite treatment.
- Elevated ESR/CRP during flares helps document episodic severity.
Pain considerations: Correlate elevated markers with symptom periods of increased pain, fatigue, and disability.
Complement Components C3 and C4
Serum complement levels; low C3/C4 indicate complement consumption during active SLE, particularly lupus nephritis.
What to expect:
Blood test results reviewed. Low complement levels are an SLE classification criterion and correlate with disease activity.
Key thresholds:
- Low C3 (<90 mg/dL) or Low C4 (<16 mg/dL) — Supports active SLE and potential renal involvement; aids in documenting disease severity.
Tips:
- If your complement levels have been low during flares, document these episodes.
- Bring records showing complement levels at different disease activity states.
Pain considerations: N/A - laboratory test.
Joint Assessment (for RA and Gout)
Number and location of affected joints, presence of synovitis, swelling, deformity, and range of motion for RA; uric acid levels, tophi, and joint involvement for gout.
What to expect:
Physical examination of affected joints. For RA, examiner assesses bilateral small joint involvement (MCPs, PIPs, wrists), morning stiffness, and erosive disease on imaging. For gout (DC 5017), examiner evaluates frequency of acute attacks, tophi, and joint damage.
Key thresholds:
- -6 joints affected (RA) — Supports higher RA rating under DC 5002; more joints = greater functional impairment.
- Recurrent acute gout attacks — Frequency and severity of attacks affects gout rating under DC 5017.
- Tophi present (gout) — Tophaceous gout indicates chronic disease; may increase rating.
Tips:
- For RA: describe morning stiffness duration (VA considers >1 hour significant), joint swelling, grip weakness, and functional limitations.
- For gout: document each acute attack, its duration, joints involved, and any hospitalizations.
- DeLuca factors apply: describe pain on use, fatigue, weakness, incoordination, and how symptoms worsen with repetitive use and flare-ups.
- Bring imaging reports (X-rays showing erosions for RA; urate deposits for gout).
Pain considerations: Describe pain at its worst during flares, not just baseline. For RA, note that joints may look better on exam day than on your worst days. Request the examiner note this discrepancy.
Rating Criteria Breakdown
| Rating % | Criteria | Key Symptoms |
|---|---|---|
| 100% | Under DC 6350 (SLE): Active process with frequent exacerbations; OR one or more of the following: persistent anemia, thrombocytopenia, or leukopenia; impaired renal function (proteinuria, casts, elevated creatinine/BUN); CNS involvement; pleuritis or pericarditis; requiring continuous immunosuppressive or corticosteroid therapy. For RA under DC 5002: Active joint destruction with weight loss, anemia, and severe constitutional symptoms requiring systemic treatment. |
CFR: 38 CFR 4.88b, DC 6350: Total disability rating when there is active disease with multi-organ involvement or when continuous immunosuppressive therapy is required. Under DC 5002 (RA), weight loss, anemia, and severe functional impairment with systemic treatment support 100%. |
| 60% | Under DC 6350 (SLE): Exacerbations 3 or more times per year OR; requirement for systemic steroids or immunosuppressives; with objective findings of active disease. For RA under DC 5002: Symptoms well controlled with continuous medication; with at least two of the following: weight loss, anemia, swelling of at least two joints, morning stiffness, constitutional symptoms. |
CFR: Under DC 6350, exacerbations occurring 3 or more times per year with objective findings. Under DC 5002, two or more joints with active synovitis, morning stiffness, and ongoing systemic treatment. |
| 40% | Under DC 6350 (SLE): Exacerbations 2 times per year OR with continuous medication; objective findings present. For RA: Moderate disease with joint involvement, controlled with medications, with some constitutional symptoms. |
CFR: Exacerbations twice per year with objective findings; continuous use of antimalarials or DMARDs; moderate functional impairment. |
| 20% | Under DC 6350 (SLE): Exacerbations once per year OR controlled with medication; mild objective findings. For RA: Well-controlled with medication; minimal active joint findings but ongoing treatment required. |
CFR: One exacerbation per year; disease controlled with hydroxychloroquine or low-dose NSAID; mild objective findings on exam. |
| 10% | Condition controlled with medication with no incapacitating episodes; minimal objective findings. Requires ongoing monitoring and treatment but minimal functional impairment. |
CFR: Gout (DC 5017) or other autoimmune arthropathy with minimal active disease, no incapacitating attacks in past year, maintained on uric acid-lowering therapy or antimalarials. |
100% Under DC 6350 (SLE): Active process with frequent exacerbati ...
Under DC 6350 (SLE): Active process with frequent exacerbations; OR one or more of the following: persistent anemia, thrombocytopenia, or leukopenia; impaired renal function (proteinuria, casts, elevated creatinine/BUN); CNS involvement; pleuritis or pericarditis; requiring continuous immunosuppressive or corticosteroid therapy. For RA under DC 5002: Active joint destruction with weight loss, anemia, and severe constitutional symptoms requiring systemic treatment.
Key Symptoms
- Frequent disease exacerbations (multiple per year)
- Persistent hemolytic anemia or thrombocytopenia
- Lupus nephritis with impaired renal function
- CNS lupus manifestations (seizures, psychosis, neuropathy)
- Pericarditis or pleuritis requiring treatment
- Continuous oral corticosteroid or immunosuppressive therapy
- Severe constitutional symptoms: fatigue, fever, weight loss
- Inability to work or perform daily activities
CFR: 38 CFR 4.88b, DC 6350: Total disability rating when there is active disease with multi-organ involvement or when continuous immunosuppressive therapy is required. Under DC 5002 (RA), weight loss, anemia, and severe functional impairment with systemic treatment support 100%.
60% Under DC 6350 (SLE): Exacerbations 3 or more times per year ...
Under DC 6350 (SLE): Exacerbations 3 or more times per year OR; requirement for systemic steroids or immunosuppressives; with objective findings of active disease. For RA under DC 5002: Symptoms well controlled with continuous medication; with at least two of the following: weight loss, anemia, swelling of at least two joints, morning stiffness, constitutional symptoms.
Key Symptoms
- 3+ disease flares per year requiring medical intervention
- Systemic corticosteroid use (oral, not just topical)
- Active synovitis in multiple joints
- Photosensitivity with rash
- Oral ulcers
- Significant fatigue impacting daily function
- Skin manifestations (malar rash, discoid lesions)
- Morning stiffness lasting >1 hour (RA)
CFR: Under DC 6350, exacerbations occurring 3 or more times per year with objective findings. Under DC 5002, two or more joints with active synovitis, morning stiffness, and ongoing systemic treatment.
40% Under DC 6350 (SLE): Exacerbations 2 times per year OR with ...
Under DC 6350 (SLE): Exacerbations 2 times per year OR with continuous medication; objective findings present. For RA: Moderate disease with joint involvement, controlled with medications, with some constitutional symptoms.
Key Symptoms
- 2 flares per year requiring treatment changes
- Ongoing medication (DMARDs, hydroxychloroquine, low-dose steroids)
- Skin involvement (rash, photosensitivity)
- Joint pain and swelling with functional limitation
- Mild anemia or leukopenia
- Moderate fatigue affecting work capacity
CFR: Exacerbations twice per year with objective findings; continuous use of antimalarials or DMARDs; moderate functional impairment.
20% Under DC 6350 (SLE): Exacerbations once per year OR controll ...
Under DC 6350 (SLE): Exacerbations once per year OR controlled with medication; mild objective findings. For RA: Well-controlled with medication; minimal active joint findings but ongoing treatment required.
Key Symptoms
- 1 exacerbation per year requiring treatment
- Mild skin manifestations
- Well-controlled joint symptoms on maintenance medication
- Mild fatigue
- Requiring ongoing medication to maintain remission
CFR: One exacerbation per year; disease controlled with hydroxychloroquine or low-dose NSAID; mild objective findings on exam.
10% Condition controlled with medication with no incapacitating ...
Condition controlled with medication with no incapacitating episodes; minimal objective findings. Requires ongoing monitoring and treatment but minimal functional impairment.
Key Symptoms
- In remission but requiring maintenance medication
- Occasional mild symptoms
- No incapacitating episodes in past 12 months
- Continued need for follow-up care
CFR: Gout (DC 5017) or other autoimmune arthropathy with minimal active disease, no incapacitating attacks in past year, maintained on uric acid-lowering therapy or antimalarials.
How to Describe Your Symptoms
Flares and Exacerbations
How to describe:
Describe each flare as a distinct episode with specific start/end dates, duration, symptoms experienced (joint swelling, rash, fever, fatigue, organ symptoms), what treatment was required (ER visit, steroid burst, hospitalization), and how long recovery took. Quantify frequency over the past 12 months and the worst 12-month period.
Worst-day example:
“On my worst flare in [month/year], I was bedridden for 10 days with severe joint pain in both hands and knees rated 9/10, a fever of 102-F, a facial rash that made it painful to go outside, and extreme fatigue where I could not dress myself. My rheumatologist prescribed a prednisone burst of 40mg daily and I missed 2 weeks of work.”
What the examiner listens for:
Frequency of exacerbations per year, severity requiring medical intervention (ER, hospitalization, steroid changes), duration of incapacitation, and functional impact during and between flares.
Understatements to avoid:
Do not say 'I have good days and bad days' without quantifying the bad days. Do not minimize flares by saying 'it wasn't that bad' if you required medical treatment. Do not omit ER visits or medication changes during flares.
Fatigue and Energy Limitation
How to describe:
Describe fatigue as a constant feature of your condition, separate from and in addition to pain. Explain how it limits the number of hours you can be active, whether you need to rest during the day, and how it affects your ability to work, maintain the home, and care for yourself. Rate your energy on a scale and describe your worst fatigue days.
Worst-day example:
“On my worst days, I wake up already exhausted despite 9 hours of sleep. By noon I am so fatigued I must lie down for 2 hours. I cannot cook, clean, or run errands. This happens at least 3 days per week. Even on better days, my energy is maybe 50% of what it was before my diagnosis.”
What the examiner listens for:
Whether fatigue is a constant limiting factor (not just during flares), its impact on activities of daily living, work performance, and social functioning.
Understatements to avoid:
Do not say 'I get a little tired.' Do not conflate normal tiredness with lupus/RA-related fatigue. Do not fail to mention post-exertional malaise or the 'crash' after activity.
Joint Pain, Swelling, and Morning Stiffness (RA / Gout)
How to describe:
List each affected joint specifically. Describe morning stiffness duration (how long it takes joints to loosen up after waking), pain levels at rest and with activity, swelling frequency, and any deformity. For gout, describe each acute attack: which joint, duration, severity, treatment required, and inability to bear weight or use the affected limb.
Worst-day example:
“During a gout attack in my right big toe and ankle, the pain is 10/10 and I cannot walk at all for 3-5 days. Even a bedsheet touching my foot is unbearable. For my RA, my hands and wrists are stiff every morning for 90 minutes and I cannot make a fist, open jars, or type without significant pain.”
What the examiner listens for:
DeLuca factors: pain on use, pain with repetitive motion, fatigue in affected joints, weakness, incoordination, and whether symptoms are worse after use or at the end of the day. Also frequency and duration of incapacitating flares.
Understatements to avoid:
Do not demonstrate your range of motion at its best - if you can only make a fist 50% of the time, say so. Do not say pain is a 3/10 if on bad days it is a 9/10. Describe worst-day function, not average.
Skin and Mucosal Manifestations
How to describe:
Describe the location, frequency, and severity of rashes (malar butterfly rash, discoid lesions), photosensitivity, oral ulcers, and scalp involvement. Note if rashes are painful or disfiguring, affect your ability to go outdoors, and whether they leave permanent scarring (alopecia from discoid lupus).
Worst-day example:
“During flares, I develop a painful butterfly rash across my cheeks and nose that burns in sunlight. I cannot go outside without sunscreen and a hat, and even then the rash worsens. I also get oral sores on the inside of my cheeks that make eating and speaking painful for up to 2 weeks.”
What the examiner listens for:
Presence of classic lupus skin manifestations, their frequency and body surface area involvement, whether photosensitivity restricts outdoor activity, and whether scarring alopecia is present.
Understatements to avoid:
Do not minimize skin symptoms as cosmetic. Mention the functional limitation caused by photosensitivity (avoidance of outdoor activities, sunscreen requirement, UV-protective clothing).
Organ System Involvement (Renal, Cardiac, Pulmonary)
How to describe:
Clearly state any diagnosed organ complications with dates of diagnosis. For kidney disease: swelling in legs/feet, foamy urine, elevated blood pressure, any history of biopsy confirming lupus nephritis. For cardiac: any pericarditis episodes, chest pain, diagnosed pericardial effusion, heart valve issues. For lungs: pleurisy pain, shortness of breath, any diagnosed pulmonary hypertension.
Worst-day example:
“In [year], I was hospitalized for pleuritis - I had severe stabbing chest pain when breathing deeply and was placed on high-dose prednisone for 3 weeks. My nephrologist confirmed lupus nephritis class III on biopsy in [year]; I have persistent proteinuria of 1.2g/day and my creatinine runs 1.8.”
What the examiner listens for:
Documented organ system complications, their treatment intensity, and whether they represent ongoing impairment beyond the primary autoimmune rating.
Understatements to avoid:
Do not omit hospitalizations, biopsies, or specialist diagnoses. Organ complications significantly affect your rating - failing to mention them is a critical omission.
Medication Burden and Side Effects
How to describe:
List all current medications with doses and how long you have been on them. Describe side effects (weight gain from steroids, GI issues from NSAIDs, hair loss from methotrexate, increased infection risk from immunosuppressives). Emphasize if you take oral corticosteroids continuously or in frequent bursts, as this is a key rating factor.
Worst-day example:
“I have been on prednisone 10mg daily for 3 years for my lupus. This has caused me to gain 30 pounds, develop borderline diabetes, and I have had two serious infections requiring antibiotics this year because my immune system is suppressed. I also take hydroxychloroquine, mycophenolate, and a biologic injection every 2 weeks.”
What the examiner listens for:
Whether continuous oral corticosteroids or immunosuppressive/biologic therapy is required (this is a key criterion for higher ratings), medication side effects that independently impair health, and treatment-resistant disease.
Understatements to avoid:
Do not omit any medications. The DBQ specifically asks about oral corticosteroids, immunosuppressives, topical corticosteroids, and other medications - each is a separate rating factor.
Functional Impact and Occupational Limitations
How to describe:
Describe specifically how your autoimmune condition affects your ability to work (missed days, reduced hours, job changes, inability to perform physical tasks), maintain household (cooking, cleaning, childcare), and engage in social activities. Quantify: average missed workdays per month during flares, tasks you can no longer perform, assistive devices used.
Worst-day example:
“I miss work an average of 3-4 days per month during flares. I was forced to change from a job requiring physical labor to a desk job because I could no longer stand for long periods. Even at my desk job, I frequently cannot type due to hand swelling and need to take breaks every 30 minutes. I can no longer do yard work, exercise, or lift items heavier than 10 pounds.”
What the examiner listens for:
Concrete, specific functional limitations tied to the autoimmune condition; occupational impact; need for assistance with ADLs; whether the condition is the reason for unemployment or underemployment.
Understatements to avoid:
Do not say 'I manage okay' if you have significantly limited your activities. Do not omit job changes, reduced work hours, or assistance you receive from family members for daily tasks.
Common Mistakes to Avoid
Only describing symptoms on your current (good) day
Autoimmune diseases are episodic. If you are in remission on exam day, the examiner may rate you as minimally impaired. VA adjudication under M21-1 requires rating based on the full picture including worst-day and average functional state.
Instead: Explicitly state: 'Today is a relatively good day, but I want to describe my condition during flares, which represent [X] days per month.' Bring a symptom diary documenting your worst days. Describe both current state AND peak severity.
Impact: Can result in a 20% rating when 60% or higher is warranted.
Failing to report all organ system complications
Lupus and other autoimmune diseases affect multiple organ systems. Veterans often focus on joints or skin but omit renal, cardiac, pulmonary, or hematologic complications - each of which can independently affect the rating.
Instead: Review the DBQ categories (renal, cardiac, pulmonary, hematologic, neurological) before the exam and prepare to address each system. Bring specialist records from your nephrologist, cardiologist, or pulmonologist.
Impact: Missing organ involvement can reduce a 100% rating to 40-60%.
Not quantifying flare frequency precisely
The rating criteria under DC 6350 explicitly tie percentages to the number of exacerbations per year (1/year = lower rating, 3+/year = higher rating). Vague answers like 'sometimes I have flares' do not satisfy this criterion.
Instead: Count your flares over the past 12 months and the worst 12-month period. A 'flare' for rating purposes is a period requiring treatment change, ER visit, steroid burst, or functional incapacitation. Write down exact dates.
Impact: Can be the difference between 20% and 60-100%.
Minimizing medication intensity
Continuous immunosuppressive or corticosteroid therapy is explicitly listed in the SLE and RA rating criteria as a factor supporting higher ratings. Veterans often undersell their medication regimen.
Instead: Bring a complete medication list. Specify if medications are continuous (daily/ongoing) versus as-needed. Emphasize if you have been on oral prednisone, methotrexate, hydroxychloroquine, mycophenolate, azathioprine, biologics, or other immunosuppressives continuously.
Impact: Continuous immunosuppressive therapy is a criterion for 60-100% under DC 6350.
Failing to report incapacitating episodes for gout (DC 5017)
For gout under DC 5017, the rating is based on actual manifestations - frequency and severity of acute attacks, tophi, and joint damage. Veterans may omit past acute attacks that were treated at urgent care or by their primary care physician.
Instead: Document every acute gout attack in the past 2-3 years: date, joint affected, duration, treatment, and whether you were unable to work or ambulate. If you have tophi, identify their locations.
Impact: Directly determines gout rating under DC 5017.
Not mentioning the impact on employment and daily activities
The DBQ explicitly asks whether the autoimmune condition impacts employment and daily activities. Failing to address this misses an important documentation opportunity.
Instead: Prepare a concise statement describing job limitations, missed workdays, accommodations required, and tasks you can no longer perform independently. If unemployed due to the condition, state this clearly.
Impact: Extra-schedular ratings and TDIU eligibility depend on this documentation.
Not bringing laboratory results and specialist records to the exam
The DBQ has extensive laboratory fields (ANA, anti-dsDNA, anti-Smith, anti-Ro, anti-phospholipid, CBC, BMP, complement C3/C4, urinalysis, ESR, CRP, imaging). If the examiner cannot reference these, they may note them as 'not available' which weakens your claim.
Instead: Compile a binder with your most recent and historically most abnormal lab results, all serology panels, imaging reports, and specialist notes. Organize by date and highlight abnormal values.
Impact: Missing lab documentation can reduce any rating level.
Omitting coexisting autoimmune conditions
Veterans with one autoimmune disease often have overlap syndromes (e.g., SLE with Sj-gren's syndrome, RA with secondary Sj-gren's, lupus with antiphospholipid syndrome). Each may be separately ratable or affect the severity of the primary condition.
Instead: List all diagnosed autoimmune conditions regardless of whether they are currently claimed. The DBQ specifically includes checkboxes for Sj-gren's syndrome, scleroderma, polymyalgia rheumatica, Wegener's granulomatosis, Goodpasture's syndrome, and others.
Impact: Missed diagnoses may result in separate ratable conditions being overlooked entirely.
Prep Checklist
Before Your Exam
Day Of
During the Exam
After the Exam
Your Rights During a C&P Exam
- You have the right to be examined by a qualified examiner with experience in autoimmune/rheumatological conditions. If the assigned examiner lacks relevant specialty knowledge, you may document this concern in writing.
- You have the right to audio-record your C&P examination in most states. Notify the examiner at the start of the exam. Check your state's recording consent laws beforehand.
- You have the right to submit additional evidence (private medical records, specialist letters, nexus opinions, buddy statements) before and after the C&P exam. Evidence submitted within one year of the exam can be considered.
- You have the right to request a copy of the completed DBQ under the Privacy Act and FOIA. Review it for accuracy and report discrepancies to your VSO or accredited claims agent.
- You have the right to request a supplemental C&P examination if the initial exam was inadequate (examiner not qualified, exam too brief, key systems not evaluated, records not reviewed). File a notice of disagreement or supplemental claim with supporting private medical evidence.
- You have the right to bring a VSO representative, accredited attorney, accredited claims agent, or support person to accompany you to the exam.
- You have the right to have all relevant medical records - including private treating physician records, VA medical records, and prior C&P examination reports - reviewed by the examiner before forming opinions.
- Under 38 CFR 3.303 and 3.307, certain autoimmune conditions may be subject to presumptive service connection for specific categories of veterans (e.g., Agent Orange presumptives, radiation exposure, contaminated water exposure at Camp Lejeune). Ask your VSO whether a presumptive applies to your case.
- Under the benefit of the doubt standard (38 CFR 3.102), when there is an approximate balance of positive and negative evidence regarding any issue, VA must resolve the question in the veteran's favor. You are not required to prove your condition beyond a reasonable doubt.
- You have the right to have your condition rated based on its worst manifestations and typical functional impact, not solely on your presentation on the day of the exam. VA is required to rate the average impairment in earning capacity over time.
Related Conditions
- Rheumatoid Arthritis Multi joint autoimmune arthritis rated under DC 5002; may overlap with or be concurrent with SLE. Rated based on active joint destruction, constitutional symptoms, and treatment intensity.
- Gout Crystal arthropathy rated under DC 5017. Evaluated based on frequency of acute attacks, presence of tophi, and joint damage. May coexist with other autoimmune conditions.
- Sj-gren's Syndrome Autoimmune exocrine gland disorder frequently coexisting with SLE and RA (secondary Sj gren's). Listed on the autoimmune DBQ as a separately diagnosable condition.
- Lupus Nephritis Renal manifestation of SLE rated separately under kidney function criteria. Glomerulonephritis and proteinuria directly impact SLE severity rating and may be separately ratable.
- Antiphospholipid Syndrome Autoimmune coagulation disorder associated with SLE causing recurrent arterial and venous thrombosis. Separately evaluated; DBQ specifically documents recurrent thrombosis.
- Scleroderma (Systemic Sclerosis) Autoimmune connective tissue disease listed on the autoimmune DBQ as a separately diagnosable condition. May overlap with SLE in mixed connective tissue disease.
- Polymyalgia Rheumatica Inflammatory condition causing proximal muscle pain and stiffness listed on the autoimmune DBQ. Often associated with temporal arteritis/giant cell arteritis.
- Temporal Arteritis (Giant Cell Arteritis) Large vessel vasculitis often comorbid with polymyalgia rheumatica. Listed on the autoimmune DBQ as a separately diagnosable condition.
- Pulmonary Hypertension Pulmonary complication of SLE, scleroderma, and other autoimmune diseases rated separately under respiratory criteria. The autoimmune DBQ documents this as a pulmonary manifestation.
- Fibromyalgia Frequently coexists with RA and SLE, contributing to pain and fatigue burden. Rated separately under DC 5025. The overlapping symptom profile can complicate attribution but each condition is separately ratable.
- Depression / Anxiety (Secondary) Mental health conditions frequently secondary to chronic autoimmune disease due to pain, functional limitation, medication side effects, and unpredictable disease course. May be separately ratable as secondary to the autoimmune condition.
- Diabetes Mellitus Type II (Steroid-Induced) Long term oral corticosteroid use for autoimmune disease management can cause or worsen diabetes mellitus. May be separately ratable as secondary to corticosteroid treatment of the service connected autoimmune condition.
Get Personalized C&P Exam Preparation
Upload your medical records for AI-powered prep that maps YOUR symptoms to the exact DBQ fields your examiner will evaluate.
This C&P exam preparation guide is for educational purposes only and does not constitute legal, medical, or claims advice. Always consult with a qualified Veterans Service Organization (VSO) representative or VA-accredited attorney for guidance specific to your claim. Never exaggerate, minimize, or fabricate symptoms during a C&P examination.